ir.vistaprint.com
Cimpress N.V. - Investor Relations - Investor RelationsVistaprint Investor Relations
http://ir.vistaprint.com/
Vistaprint Investor Relations
http://ir.vistaprint.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
16x16
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
0
SITE IP
184.51.0.249
LOAD TIME
0 sec
SCORE
6.2
Cimpress N.V. - Investor Relations - Investor Relations | ir.vistaprint.com Reviews
https://ir.vistaprint.com
Vistaprint Investor Relations
Cimpress N.V. - Shareholder Meetings - Investor Relations
Financial Reports and Presentations. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS. Cimpress N.V. will hold an Extraordinary General Meeting of Shareholders:. On Monday, January 12, 2015. At 8:00 pm Central European Time. At the offices of Stibbe. Notice of Extraordinary General Meeting of Shareholders. Draft Deed of Amendment of the Articles of Association. To review the documents above, click on the respective links. To view the PDF version, you will need Adobe Acrobat; click here.
Welcome » Investors » VirnetX
Seamless, Automatic, Internet Security. Seamless, Automatic, Internet Security. GABRIEL CONNECTION TECHNOLOGY WHITE PAPER. ROYALTY RATES AND GUIDELINES. VirnetX: Seamless, Automatic, Internet Security. Zephyr Cove, NV 89448. Phone: 775.548.1785. Fax: 775.580.7527. Zephyr Cove, NV 89448. 2014 VirnetX. Privacy policy.
Default Web Site Page
If you are the owner of this website, please contact your hosting provider: webmaster@ir.virtualrad.com. It is possible you have reached this page because:. The IP address has changed. The IP address for this domain may have changed recently. Check your DNS settings to verify that the domain is set up correctly. It may take 8-24 hours for DNS changes to propagate. It may be possible to restore access to this site by following these instructions. For clearing your dns cache.
Virtus Investment Partners - Investor Relations
Virtus provides investment management services through affiliated managers and carefully selected unaffiliated subadvisers, each with a distinct investment philosophy, autonomous investment process and individual brand. View Our Investment Managers. Introducing the Virtus Trend Funds. Rules-based, risk-managed funds for the investor seeking defensive equity exposure. Reports and SEC Filings. Duff and Phelps Investment Management. Kayne Anderson Rudnick Investment Management. And Virtus ETF Solutions.
Vishay Intertechnology |
Vishay Intertechnology, Inc. Vishay Reports Results For Second Quarter 2015. Q2 2015 Earnings Slides. Q2 2015 Form 10-Q. The most recent, real-time Vishay filings as they are procecessed by the SEC. At-a-glance information on how VSH is doing.
Vistamar School Information Resources
The Information Literacy Program at Vistamar strives to impart in our students learning and research skills aimed at technological literacy. Through new and intensive approaches and training, the program fuses library and technological skills with critical thinking, ethics, and communication skills. These competencies are common in all disciplines and at all levels of education. They also form an integral part in our global perspective in education. Formulating a Search Strategy.
Cimpress N.V. - Investor Relations - Investor Relations
Cimpress N.V. (Nasdaq: CMPR) is the world leader in mass customization. For 20 years, the company has focused on developing software and manufacturing capabilities that transform traditional markets in order to make customized products accessible and affordable to everyone. Financial Reports and Presentations. Cimpress NV Investor Day 2015. 160;at 8:30 am ET. Cimpress NV Fourth Quarter Fiscal Year 2015 Earnings Live Q&A session. 160;at 7:30 am ET. Cimpress Q4 Fiscal Year 2015 Earnings Press Release.
Vita34
Mo-Fr 8:00 – 19:00. Decl of Compliance and Report. Report of the Sup. Board. Annual financial report 2017 (PDF). DGAP-DD: Vita 34 AG english. Welcome to the Vita 34 AG Investor Relations website. We would be more than happy to answer your questions directed at ir@vita34group.de. Deutscher Platz 5 04103 Leipzig, Germany Phone: 49 (0)341 48792-40. Fax: 49 (0)341 48792-39 E-Mail: ir@vita34.com.
Vita34
Produkte von Vita 34. Mo-Fr 8:00 – 19:00. Erklärung zur Unternehmensführung und Bericht. Veröffentlichung gemäß 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung. Herzlich Willkommen auf der Internetseite Investor Relations der Vita 34 AG. Gerne beantworten wir Ihre Fragen unter ir@vita34group.de. Deutscher Platz 5 04103 Leipzig Tel: 49 341 487 9240. Fax: 49 341 487 9239 E-Mail: ir@vita34.de. Kostenfreie Beratung zur Einlagerung von Stammzellen. Unter 0800 034 0000 (Deutschland).
VIVER
History and Corporate Profile. Vision, Mission and Values. Board of Executive Officers. Presentations and Conference Calls. Announcements and Notices to Shareholders. Minutes and Documents for Meetings. History and Corporate Profile. Vision, Mission and Values. Board of Executive Officers. Presentations and Conference Calls. Announcements and Notices to Shareholders. Minutes and Documents for Meetings. Presentations and Conference Calls. Is a format of Internet news distribution, such as VIVER's.
Viveve Medical, Inc. (VIVMF)
Talk of the Town. Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women’s health company based in Sunnyvale, California. The company is focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Viveve treats the condition of vaginal laxity, which is the result of the over stretching of the vaginal tissue during childbirth. Aug 11, 2015 8:28 AM EDT. Sign Up For Email Alerts. August 14, 2015.
Investor Relations | VIVUS, Inc.
Skip to main navigation. Stock Information Historical Lookup. Financial Information SEC Filings. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. Mar 13, 2018. VIVUS Reports Fourth Quarter 2017 Financial Results. Dec 26, 2017. View All Press Releases.
